New treatments for atopic dermatitis

Williams, Hywel (2002) New treatments for atopic dermatitis. British Medical Journal, 324 . pp. 1533-1534.

[img] PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (163kB)

Abstract

Atopic dermatitis now affects 15% to 20% of chil­

dren in developed countries, and prevalence

in cities in developing countries undergoing

rapid demographic changes is quickly following suit.1

Most cases of atopic dermatitis in a given community

are mild, but children with moderate to severe disease

can have continuous itching and associated loss of

sleep. The social stigma of a visible skin disease can also

be soul destroying for both patient and family. A few

studies have suggested that some degree of prevention

of the disease is possible,2 although these measures

have not been taken up widely. In the absence of any

treatment that is known to alter the clinical course of

the disease, most treatment is aimed at reducing symp­

toms and signs. After a relative lull of almost 40 years,

new drugs—tacrolimus and pimecrolimus—have

appeared that offer different approaches to managing

this miserable disease. Do they work? Are they safe?

And how do they compare with existing treatments?

Item Type: Article
Schools/Departments: University of Nottingham UK Campus > Faculty of Medicine and Health Sciences > School of Medicine
Depositing User: attreed, karen
Date Deposited: 20 Mar 2008 11:49
Last Modified: 20 Mar 2008 11:49
URI: http://eprints.nottingham.ac.uk/id/eprint/862

Actions (Archive Staff Only)

Edit View Edit View